Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eagle Capital Growth Fund (GRF)

Eagle Capital Growth Fund (GRF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 6,813 K
  • Annual Income, $ 6,622 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade GRF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.96 +10.64%
on 10/28/20
7.88 -2.23%
on 11/27/20
+0.57 (+8.00%)
since 10/27/20
3-Month
6.65 +15.80%
on 09/25/20
7.88 -2.23%
on 11/27/20
+0.55 (+7.70%)
since 08/27/20
52-Week
5.20 +48.08%
on 03/23/20
8.24 -6.55%
on 02/18/20
+0.05 (+0.71%)
since 11/27/19

Most Recent Stories

More News
Eagle Capital Growth Fund Declares Year-End Distribution of $0.55 Per Share

Eagle Capital Growth Fund, Inc. ("Fund") (NYSE American: GRF) today declared a year-end cash distribution of $0.55 per share. The record date for this distribution is December 4, 2020, and the payment...

GRF : 7.70 (-1.34%)
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies

, /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more than 100 years of history contributing...

GRF : 7.70 (-1.34%)
GRFS : 18.69 (+2.64%)
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies

BARCELONA, Spain , Nov. 16, 2020 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with...

GRFS : 18.69 (+2.64%)
GRF : 7.70 (-1.34%)
Grifols partners with TRC Healthcare to streamline intravenous compounding education

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and provider of technologies and services for hospitals, clinics and compounding...

GRF : 7.70 (-1.34%)
GRFS : 18.69 (+2.64%)
Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...

GRF : 7.70 (-1.34%)
GRFS : 18.69 (+2.64%)
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

- - - - , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's leading producers of plasma-derived medicines, today announced the closing...

GRF : 7.70 (-1.34%)
GRFS : 18.69 (+2.64%)
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

, and , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...

GRF : 7.70 (-1.34%)
GRFS : 18.69 (+2.64%)
ICU Medical Broadens its Non-PVC/Non-DEHP IV Solutions Portfolio by Entering Long-Term U.S. Distribution Agreement with Grifols for Certain Core IV Solution Products

SAN CLEMENTE, Calif., /PRNewswire/ --  (NASDAQ: ICUI) today announced that it has entered into a long-term agreement with to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium...

ICUI : 186.78 (+1.01%)
GRF : 7.70 (-1.34%)
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...

GRF : 7.70 (-1.34%)
GRFS : 18.69 (+2.64%)
Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

and , /PRNewswire/ -- A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor...

MSFT : 215.23 (+0.64%)
GRF : 7.70 (-1.34%)
GRFS : 18.69 (+2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

GRF Dividends

Date Value
11/21/19 $0.5600
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar